"Discarding a batch of bulk drug substance, while disappointing, does occasionally happen during vaccine manufacturing, which is a complex and multi-step biological process." Johnson & Johnson said it is continuing to work with the FDA and Emergent toward the authorization of the facility. J&J said that it sent additional quality, manufacturing and technical operations experts to be on site to supervise and support the manufacturing of their vaccine. J&J 's supply will fluctuate, adding additional 4 to 6 million doses weekly to 16 million per month. Kates added that if there is any kind of delay with J&J vaccine, it could negatively impact people who are harder to reach.

Source: CNN April 01, 2021 23:37 UTC